LY
LYRA.US Lyra Therapeutics Inc
- Market cap
- USD 337K
- P/E
- -
- P/B
- 7.10x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is LYRA.US undervalued?
Graham numberThe Graham number of Lyra Therapeutics Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Lyra Therapeutics Inc fundamental analysis
No fundamental analysis for Lyra Therapeutics Inc yet.
Lyra Therapeutics Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Lyra Therapeutics Inc
Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of anti-inflammatory therapies for the treatment of patients with chronic rhinosinusitis. Its technology is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix which is in Phase III clinical trial for the tre…
Full company profileLyra Therapeutics Inc financial statements
Lyra Therapeutics Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 1.24M | 0.00 | 0.00 | 285K | 1.36M | 1.56M | 1.53M | 398K |
| Gross Profit | 1.24M | -27.0K | -12.5M | 285K | 1.36M | 1.56M | 1.53M | 398K |
| Operating Income | -7.26M | -16.5M | -22.2M | -43.6M | -56.3M | -67.1M | -96.3M | -31.0M |
| EBITDA | -7.18M | -16.5M | -22.1M | -42.6M | -53.9M | -65.3M | -60.3M | -29.1M |
| Net Income | -6.03M | -16.3M | -22.1M | -42.4M | -55.3M | -62.7M | -93.4M | -28.9M |
| EPS | -0.96 | -1.99 | -2.58 | -3.27 | -1.83 | -1.26 | -1.43 | -1.86 |
| Balance Sheet | ||||||||
| Total Assets | 25.4M | 15.0M | 80.8M | 54.9M | 110M | 143M | 66.3M | 36.1M |
| Total Liabilities | 132M | 7.64M | 6.34M | 20.6M | 29.2M | 53.2M | 54.8M | 46.8M |
| Shareholders' Equity | -107M | 7.33M | 74.5M | 34.3M | 80.8M | 89.4M | 11.6M | -10.7M |
| Cash & Short-term Investments | 23.9M | 9.81M | 74.6M | 45.7M | 97.9M | 103M | 40.6M | 15.9M |
| Total Debt | - | 3.33M | 2.44M | 1.45M | 4.18M | 26.9M | 34.4M | 30.3M |
| Cash Flow | ||||||||
| Operating Cash Flow | -6.64M | -13.8M | -21.1M | -25.8M | -43.4M | -63.3M | -70.0M | -28.9M |
| Capital Expenditure | 37.0K | 211K | 1.78M | 3.39M | 164K | 1.05M | 2.34M | 116K |
| Free Cash Flow | -6.68M | -14.0M | -22.9M | -29.2M | -43.5M | -64.4M | -72.3M | -29.0M |
| Ratios | ||||||||
| ROE | - | -222.5% | -29.7% | -123.6% | -68.5% | -70.1% | -805.9% | - |
| ROA | -23.8% | -109.0% | -27.4% | -77.3% | -50.3% | -44.0% | -140.8% | -80.1% |
| Net Profit Margin | -484.6% | - | - | -14,880.7% | -4,055.6% | -4,023.1% | -6,090.9% | -7,266.1% |
| Debt to Equity | - | 0.45x | 0.03x | 0.04x | 0.05x | 0.30x | 2.97x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Lyra Therapeutics Inc dividends
Lyra Therapeutics Inc has not paid dividends in the last 8 fiscal years.
Last stock split: 1:50 on May 28, 2025.
Who owns Lyra Therapeutics Inc
- Insiders 0.62%
- Institutions 6.64%
- Public & others 92.74%
- Shares outstanding 1.77M
- Free float 440K
Top funds holding LYRA.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Extended Equity Market Fund B | 1.63K | 0.09% | 0.00% | Dec 2025 |
| Extended Equity Market Fund E | 1.63K | 0.09% | 0.00% | Dec 2025 |
Top institutions holding LYRA.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Sabby Management LLC | 104K | 5.86% | -40.59% | Mar 2026 |
| EverSource Wealth Advisors, LLC | 0.00 | 0.00% | -100.00% | Mar 2026 |
| Bryn Mawr Trust Company | 0.00 | 0.00% | -100.00% | Mar 2026 |
| DRW Securities, LLC | 0.00 | 0.00% | -100.00% | Mar 2026 |
| Ikarian Capital, LLC | 0.00 | 0.00% | -100.00% | Mar 2026 |
| BlackRock Inc | 0.00 | 0.00% | -100.00% | Mar 2026 |
| Royal Bank of Canada | 0.00 | 0.00% | -100.00% | Mar 2026 |
| Tower Research Capital LLC | 0.00 | 0.00% | -100.00% | Mar 2026 |
| Citigroup Inc | 0.00 | 0.00% | -100.00% | Mar 2026 |
| Global Retirement Partners, LLC. | 0.00 | 0.00% | -100.00% | Jun 2026 |
| UBS Group AG | 0.00 | 0.00% | -100.00% | Mar 2026 |
| BNP Paribas Arbitrage, SA | 0.00 | 0.00% | -100.00% | Mar 2026 |
| Morgan Stanley - Brokerage Accounts | 0.00 | 0.00% | -100.00% | Mar 2026 |
| Artia Global Partners LP | 0.00 | 0.00% | -100.00% | Mar 2026 |
| Geode Capital Management, LLC | 0.00 | 0.00% | -100.00% | Mar 2026 |
| JONES FINANCIAL COMPANIES LLLP | 0.00 | 0.00% | -100.00% | Mar 2026 |
| JPMorgan Chase & Co | 0.00 | 0.00% | -100.00% | Mar 2026 |
| SBI Securities Co Ltd | 0.00 | 0.00% | -100.00% | Mar 2026 |
| Advisor Group Holdings, Inc. | 0.00 | 0.00% | -100.00% | Mar 2026 |
| IFP Advisors, LLC | 0.00 | 0.00% | -100.00% | Mar 2026 |
Lyra Therapeutics Inc company profile
- Company name
- Lyra Therapeutics Inc
- Ticker
- LYRA.US
- Exchange
- USA Stocks
- Listed since
- May 1, 2020
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 27
- Fiscal year end
- December
- Address
- 480 Arsenal Way, Watertown, MA, United States, 02472
- Phone
- 617 393 4600
- Website
- lyratherapeutics.com
About Lyra Therapeutics Inc
Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of anti-inflammatory therapies for the treatment of patients with chronic rhinosinusitis. Its technology is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix which is in Phase III clinical trial for the treatment of chronic rhinosinusitis (CRS); and LYR-220 for CRS patients who have failed previous medical management and continue to require treatment to manage CRS symptoms. It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.
Lyra Therapeutics Inc management
4- Dr. Carmichael S. Roberts Jr., M.B.A., Ph.D.Co-Founder · born 1968
- Ms. Vineeta Belanger Ph.D.Senior Vice President of Clinical Affairs
- Ms. Allison NanceSenior Vice President of Regulatory Affairs
- Dr. Elazer R. Edelman FACC, M.D., Ph.D.VP of Finance & Risk · born 1957